BioSpace News Archive

Dave Schwartzman brings more than twenty-five years of industry experience to new role for Demers and Crestline brands

On January 2, 2020, Health Share of Oregon learned that the personal information of its members was located on a laptop stolen from GridWorks IC, Health Share’s contracted non-emergent medical transportation vendor.

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020 after the close of the U.S. financial markets.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present at the 2020 BIO CEO & Investor Conference being held on February 10-11, 2020 at the Marriott Marquis in New York, NY.

Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that fourth quarter and fiscal year 2019 financial results will be released after the market closes on Thursday, March 12th.

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that a presentation of additional clinical study data on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2020 meeting being held on February 8, 2020, in Miami, Florida.

Intersect ENT, Inc. (Nasdaq: XENT), today announced that management will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at the Lotte New York Palace in New York City, and will present in a session at 2:30 p.m. ET.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today reported promising interim clinical results from the ongoing Phase 1/2a studies of its two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a potential treatment for patients with severe hypertriglyceridemia, and ARO-ANG3 targeting angiopoietin like protein 3 (ANGPTL3) being developed as a potential treatment for dyslipidemias and metabolic diseases.

Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release fourth quarter and year 2019 financial results on February 24, 2020.

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the 9th Annual Leerink Partners Global Healthcare Conference in New York City.